Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro

Cancer Gene Therapy volume 24, pages 45–47 (2017)Cite this article

Subjects

Abstract

We previously described the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. The isolated variant is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared with 2 of 12 of the parental cell line. OBP-401 is a telomerase-dependent cancer-specific, green fluorescent protein (GFP)-expressing adenovirus. OBP-401 was used to infect parental MDA-MB-231P cells and high-metastatic MDA-MB-231H and MDA-MB-231HLN isolated from a lymph node metastasis and MDA-MB-231HLM isolated from a lung metastasis. Time-course imaging showed that OBP-401 labeled MDA-MB-231HP, MDA-MB-231HLN, and MDA-MB-231HLM cells more brightly than MDA-MB-231 parental cells. OBP-401 killed MDA-MB-231H, MDA-MB-231HLN, and MDA-MB-231HLM cells more efficiently than MDA-MB-231P parental cells. These results indicate that OBP-401 could infect, label and then kill high-metastatic MDA-MB-231 more efficiently than low-metastatic MDA-MB-231.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Devita VT Jr, Lawrence TS, Rosenberg SA (eds). 2015 Devita, Hellman and Rosenberg’s Cancer: Principles and Practice on Oncology (Cancer Principle and Practice of Oncology) 10th ednWolters Kluwer Health: (USA) .

    Google Scholar 

  2. Foulkes WD, Smith IE, Reis-Filho JS . Triple-negative breast cancer. N Engl J Med 2010; 363: 1938–1948.

    Article  CAS  Google Scholar 

  3. Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y et al. In vivo isolation of a highly-aggressive variant of triple-negative human breast cancer variant MDA-MB-231 using serial orthotopic transplantation. Anticancer Res 2016; 36: 3817–3820.

    Article  CAS  Google Scholar 

  4. Yano S, Takehara K, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T et al. Comparison of in vitro invasiveness of high- and low-metastatic triple negative human breast cancer visualized by color-coded imaging. In Vitro Cell Dev Biol-Animal. (e-pub ahead of print).

  5. Yano S, Takehara K, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T et al, High-metastatic triple-negative breast cancer variants selected in vivo become chemoresistant in vitro. In Vitro Cell Dev Biol Anim (in press).

  6. Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M et al. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells into S/G2/M phases. Clin. Cancer Res 2013; 19: 6495–6505.

    Article  CAS  Google Scholar 

  7. Uchugonova A, Zhao M, Weinigel M, Zhang Y, Bouvet M, Hoffman RM et al. Multiphoton tomography visualizes collagen fibers in the tumor microenvironment that maintain cancer-cell anchorage and shape. J Cell Biochem 2013; 114: 99–102.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the National Cancer Institute grants CA 132971 and CA142669. This study was also supported in part by grants from the Ministry of Health, Labour, and Welfare, Japan (to T Fujiwara; No. 10103827, No. 13801426 and No. 14525167) and grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to T Fujiwara; No. 25293283).

Author information

Authors and Affiliations

  1. AntiCancer, Inc., San Diego, CA, USA

    S Yano, K Takehara & R M Hoffman

  2. Department of Surgery, University of California, San Diego, CA, USA

    S Yano, K Takehara, M Bouvet & R M Hoffman

  3. Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    S Yano, K Takehara, H Kishimoto, S Kagawa & T Fujiwara

  4. Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

    H Tazawa

  5. Oncolys BioPharm Inc., Tokyo, Japan

    Y Urata

Authors
  1. S Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Kishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Tazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Urata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Kagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Bouvet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R M Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to T Fujiwara or R M Hoffman.

Ethics declarations

Competing interests

YU is the President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-401 (Telomescan). HT and TF are consultants of Oncolys BioPharma, Inc. The remaining authors declare no conflict of interest.

Additional information

This paper is dedicated to the memory of A.R. Moossa, MD, and Sun Lee, MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yano, S., Takehara, K., Kishimoto, H. et al. OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro. Cancer Gene Ther 24, 45–47 (2017). https://doi.org/10.1038/cgt.2016.67

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2016.67

This article is cited by

Search

Advanced search

Quick links